牛牛AI助理已提取核心訊息
AbbVie Inc. has reported preliminary financial results for the fourth quarter of 2023, including an acquired IPR&D and milestones expense of $282 million on a pre-tax basis. This expense is expected to unfavorably impact both GAAP and adjusted non-GAAP diluted earnings per share by $0.15. The results for the quarter ending December 31, 2023, are not yet finalized and are subject to financial statement closing procedures. AbbVie has stated that there is no assurance that the final results will not differ from these preliminary estimates. The company does not forecast acquired IPR&D and milestones expense due to the uncertainty of future transactions. AbbVie's full-year 2023 adjusted diluted earnings per share guidance, including the impact of the fourth quarter expense, is...Show More
AbbVie Inc. has reported preliminary financial results for the fourth quarter of 2023, including an acquired IPR&D and milestones expense of $282 million on a pre-tax basis. This expense is expected to unfavorably impact both GAAP and adjusted non-GAAP diluted earnings per share by $0.15. The results for the quarter ending December 31, 2023, are not yet finalized and are subject to financial statement closing procedures. AbbVie has stated that there is no assurance that the final results will not differ from these preliminary estimates. The company does not forecast acquired IPR&D and milestones expense due to the uncertainty of future transactions. AbbVie's full-year 2023 adjusted diluted earnings per share guidance, including the impact of the fourth quarter expense, is projected to be between $11.04 and $11.08. The guidance for the fourth quarter adjusted diluted earnings per share, also including this expense, is estimated to be between $2.72 and $2.76. The company has furnished this information as Exhibit 99.1 to the Current Report on Form 8-K. AbbVie has also cautioned that forward-looking statements in the report are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied.
艾伯維公司公佈了2023年第四季度的初步財務業績，包括收購的IPR&D和稅前2.82億美元的里程碑支出。預計該支出將對GAAP和調整後的非GAAP攤薄後每股收益產生0.15美元的不利影響。截至2023年12月31日的季度業績尚未最終確定，須遵守財務報表結算程序。艾伯維表示，無法保證最終結果不會與這些初步估計有所不同。由於未來交易的不確定性，該公司不預測收購的知識產權研發和里程碑費用。艾伯維2023年全年調整後的攤薄後每股收益指引，包括第四季度支出的影響，預計將在11.04美元至11.08美元之間。第四季度調整後的攤薄後每股收益（包括這筆支出）的預期在2.72美元至2.76美元之間。該公司已將這些信息作爲當前8-K表報告的附錄99.1提供。艾伯維還警告說，報告中的前瞻性陳述存在風險和不確定性，可能導致實際業績與明示或暗示的結果存在重大差異。
艾伯維公司公佈了2023年第四季度的初步財務業績，包括收購的IPR&D和稅前2.82億美元的里程碑支出。預計該支出將對GAAP和調整後的非GAAP攤薄後每股收益產生0.15美元的不利影響。截至2023年12月31日的季度業績尚未最終確定，須遵守財務報表結算程序。艾伯維表示，無法保證最終結果不會與這些初步估計有所不同。由於未來交易的不確定性，該公司不預測收購的知識產權研發和里程碑費用。艾伯維2023年全年調整後的攤薄後每股收益指引，包括第四季度支出的影響，預計將在11.04美元至11.08美元之間。第四季度調整後的攤薄後每股收益（包括這筆支出）的預期在2.72美元至2.76美元之間。該公司已將這些信息作爲當前8-K表報告的附錄99.1提供。艾伯維還警告說，報告中的前瞻性陳述存在風險和不確定性，可能導致實際業績與明示或暗示的結果存在重大差異。
有用
沒用